Thirty-four cases of CIN and 111 cases of renal function decline were identified during mean follow-up of 2.3 ± 1.3 years. Patients with higher FGF21 concentration were older, had higher incidence of hypertension, diabetes, chronic kidney disease, and heart failure. All subjects were followed up till December 2016, or till the occurrence of major adverse cardiovascular events (MACE). Renal function decline was defined as >30% reduction of eGFR from baseline. Creatinine was obtained 48 hours after CAG, and every 6 months in the follow-up period. Patients were grouped into tertiles according to their FGF21 concentration. Baseline creatinine and FGF21 were obtained before CAG. To investigate the impact of FGF21 on contrast-induced nephropathy (CIN), 531 subjects underwent elective coronary angiography (CAG) were enrolled. Its impact on non-diabetic kidney disease is unclear. Fibroblast growth factor 21 (FGF21) is a regulator of glucose homeostasis, and is suggested to have protective effect on diabetic nephropathy.
0 kommentar(er)
